7 results on '"Filippatos, Gerasimos"'
Search Results
2. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes
- Author
-
Pitt, Bertram, primary, Filippatos, Gerasimos, additional, Agarwal, Rajiv, additional, Anker, Stefan D., additional, Bakris, George L., additional, Rossing, Peter, additional, Joseph, Amer, additional, Kolkhof, Peter, additional, Nowack, Christina, additional, Schloemer, Patrick, additional, and Ruilope, Luis M., additional
- Published
- 2021
- Full Text
- View/download PDF
3. Empagliflozin and Major Renal Outcomes in Heart Failure
- Author
-
Packer, Milton, primary, Butler, Javed, additional, Zannad, Faiez, additional, Pocock, Stuart J., additional, Filippatos, Gerasimos, additional, Ferreira, João P., additional, Brueckmann, Martina, additional, Jamal, Waheed, additional, Zeller, Cordula, additional, Wanner, Christoph, additional, and Anker, Stefan D., additional
- Published
- 2021
- Full Text
- View/download PDF
4. Empagliflozin in Heart Failure with a Preserved Ejection Fraction
- Author
-
Anker, Stefan D., primary, Butler, Javed, additional, Filippatos, Gerasimos, additional, Ferreira, João P., additional, Bocchi, Edimar, additional, Böhm, Michael, additional, Brunner–La Rocca, Hans-Peter, additional, Choi, Dong-Ju, additional, Chopra, Vijay, additional, Chuquiure-Valenzuela, Eduardo, additional, Giannetti, Nadia, additional, Gomez-Mesa, Juan Esteban, additional, Janssens, Stefan, additional, Januzzi, James L., additional, Gonzalez-Juanatey, Jose R., additional, Merkely, Bela, additional, Nicholls, Stephen J., additional, Perrone, Sergio V., additional, Piña, Ileana L., additional, Ponikowski, Piotr, additional, Senni, Michele, additional, Sim, David, additional, Spinar, Jindrich, additional, Squire, Iain, additional, Taddei, Stefano, additional, Tsutsui, Hiroyuki, additional, Verma, Subodh, additional, Vinereanu, Dragos, additional, Zhang, Jian, additional, Carson, Peter, additional, Lam, Carolyn Su Ping, additional, Marx, Nikolaus, additional, Zeller, Cordula, additional, Sattar, Naveed, additional, Jamal, Waheed, additional, Schnaidt, Sven, additional, Schnee, Janet M., additional, Brueckmann, Martina, additional, Pocock, Stuart J., additional, Zannad, Faiez, additional, and Packer, Milton, additional
- Published
- 2021
- Full Text
- View/download PDF
5. Ferric Carboxymaltose in Heart Failure with Iron Deficiency.
- Author
-
Anker, Stefan D., Filippatos, Gerasimos, and Anker, Markus S.
- Subjects
- *
IRON deficiency , *HEART failure - Abstract
The article discusses the ambiguity in defining iron deficiency in heart failure patients, focusing on the differentiation between absolute and functional iron deficiency. Topics include discrepancies in defining iron deficiency in heart failure trials, considerations of ferritin levels and transferrin saturation, and the impact of intravenous iron treatment on mortality.
- Published
- 2023
- Full Text
- View/download PDF
6. Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction.
- Author
-
Solomon SD, McMurray JJV, Vaduganathan M, Claggett B, Jhund PS, Desai AS, Henderson AD, Lam CSP, Pitt B, Senni M, Shah SJ, Voors AA, Zannad F, Abidin IZ, Alcocer-Gamba MA, Atherton JJ, Bauersachs J, Chang-Sheng M, Chiang CE, Chioncel O, Chopra V, Comin-Colet J, Filippatos G, Fonseca C, Gajos G, Goland S, Goncalvesova E, Kang S, Katova T, Kosiborod MN, Latkovskis G, Lee AP, Linssen GCM, Llamas-Esperón G, Mareev V, Martinez FA, Melenovský V, Merkely B, Nodari S, Petrie MC, Saldarriaga CI, Saraiva JFK, Sato N, Schou M, Sharma K, Troughton R, Udell JA, Ukkonen H, Vardeny O, Verma S, von Lewinski D, Voronkov L, Yilmaz MB, Zieroth S, Lay-Flurrie J, van Gameren I, Amarante F, Kolkhof P, and Viswanathan P
- Abstract
Background: Steroidal mineralocorticoid receptor antagonists reduce morbidity and mortality among patients with heart failure and reduced ejection fraction, but their efficacy in those with heart failure and mildly reduced or preserved ejection fraction has not been established. Data regarding the efficacy and safety of the nonsteroidal mineralocorticoid receptor antagonist finerenone in patients with heart failure and mildly reduced or preserved ejection fraction are needed., Methods: In this international, double-blind trial, we randomly assigned patients with heart failure and a left ventricular ejection fraction of 40% or greater, in a 1:1 ratio, to receive finerenone (at a maximum dose of 20 mg or 40 mg once daily) or matching placebo, in addition to usual therapy. The primary outcome was a composite of total worsening heart failure events (with an event defined as a first or recurrent unplanned hospitalization or urgent visit for heart failure) and death from cardiovascular causes. The components of the primary outcome and safety were also assessed., Results: Over a median follow-up of 32 months, 1083 primary-outcome events occurred in 624 of 3003 patients in the finerenone group, and 1283 primary-outcome events occurred in 719 of 2998 patients in the placebo group (rate ratio, 0.84; 95% confidence interval [CI], 0.74 to 0.95; P = 0.007). The total number of worsening heart failure events was 842 in the finerenone group and 1024 in the placebo group (rate ratio, 0.82; 95% CI, 0.71 to 0.94; P = 0.006). The percentage of patients who died from cardiovascular causes was 8.1% and 8.7%, respectively (hazard ratio, 0.93; 95% CI, 0.78 to 1.11). Finerenone was associated with an increased risk of hyperkalemia and a reduced risk of hypokalemia., Conclusions: In patients with heart failure and mildly reduced or preserved ejection fraction, finerenone resulted in a significantly lower rate of a composite of total worsening heart failure events and death from cardiovascular causes than placebo. (Funded by Bayer; FINEARTS-HF ClinicalTrials.gov number, NCT04435626.)., (Copyright © 2024 Massachusetts Medical Society.)
- Published
- 2024
- Full Text
- View/download PDF
7. Transcatheter Valve Repair in Heart Failure with Moderate to Severe Mitral Regurgitation.
- Author
-
Anker SD, Friede T, von Bardeleben RS, Butler J, Khan MS, Diek M, Heinrich J, Geyer M, Placzek M, Ferrari R, Abraham WT, Alfieri O, Auricchio A, Bayes-Genis A, Cleland JGF, Filippatos G, Gustafsson F, Haverkamp W, Kelm M, Kuck KH, Landmesser U, Maggioni AP, Metra M, Ninios V, Petrie MC, Rassaf T, Ruschitzka F, Schäfer U, Schulze PC, Spargias K, Vahanian A, Zamorano JL, Zeiher A, Karakas M, Koehler F, Lainscak M, Öner A, Mezilis N, Theofilogiannakos EK, Ninios I, Chrissoheris M, Kourkoveli P, Papadopoulos K, Smolka G, Wojakowski W, Reczuch K, Pinto FJ, Wiewiórka Ł, Kalarus Z, Adamo M, Santiago-Vacas E, Ruf TF, Gross M, Tongers J, Hasenfuss G, Schillinger W, and Ponikowski P
- Abstract
Background: Whether transcatheter mitral-valve repair improves outcomes in patients with heart failure and functional mitral regurgitation is uncertain., Methods: We conducted a randomized, controlled trial involving patients with heart failure and moderate to severe functional mitral regurgitation from 30 sites in nine countries. The patients were assigned in a 1:1 ratio to either transcatheter mitral-valve repair and guideline-recommended medical therapy (device group) or medical therapy alone (control group). The three primary end points were the rate of the composite of first or recurrent hospitalization for heart failure or cardiovascular death during 24 months; the rate of first or recurrent hospitalization for heart failure during 24 months; and the change from baseline to 12 months in the score on the Kansas City Cardiomyopathy Questionnaire-Overall Summary (KCCQ-OS; scores range from 0 to 100, with higher scores indicating better health status)., Results: A total of 505 patients underwent randomization: 250 were assigned to the device group and 255 to the control group. At 24 months, the rate of first or recurrent hospitalization for heart failure or cardiovascular death was 37.0 events per 100 patient-years in the device group and 58.9 events per 100 patient-years in the control group (rate ratio, 0.64; 95% confidence interval [CI], 0.48 to 0.85; P = 0.002). The rate of first or recurrent hospitalization for heart failure was 26.9 events per 100 patient-years in the device group and 46.6 events per 100 patient-years in the control group (rate ratio, 0.59; 95% CI, 0.42 to 0.82; P = 0.002). The KCCQ-OS score increased by a mean (±SD) of 21.6±26.9 points in the device group and 8.0±24.5 points in the control group (mean difference, 10.9 points; 95% CI, 6.8 to 15.0; P<0.001). Device-specific safety events occurred in 4 patients (1.6%)., Conclusions: Among patients with heart failure with moderate to severe functional mitral regurgitation who received medical therapy, the addition of transcatheter mitral-valve repair led to a lower rate of first or recurrent hospitalization for heart failure or cardiovascular death and a lower rate of first or recurrent hospitalization for heart failure at 24 months and better health status at 12 months than medical therapy alone. (Funded by Abbott Laboratories; RESHAPE-HF2 ClinicalTrials.gov number, NCT02444338.)., (Copyright © 2024 Massachusetts Medical Society.)
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.